ASX Share rice
Tue 04 Aug 2020 - 02:48:pm (Sydney)

CP1 Share Price

CANNPAL ANIMAL THERAPEUTICS LIMITEDCP1Pharmaceuticals, Biotechnology & Life Sciences

CP1 Company Information


CannPal Animal Therapeutics Limited




Drug Manufacturers—Specialty & Generic

GIC Industry:


GIC Sub Industry:



45a Bay Street Double Bay NSW Australia 2028


61 2 6108 3622

Founder, MD & Director:

Mr. Layton Patrick Mills

Head of Clinical Devel. and R&D:

Dr. Margaret Curtis

CFO & Company Sec.:

Mr. Baden Maxwell Bowen

Chief Scientific Officer & Member of Advisory Board:

Dr. Rayson Tan

Company Overview:

CannPal Animal Therapeutics Limited engages in the research and development of animal health products in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat animals. The company was incorporated in 2016 and is based in Double Bay, Australia.

CP1 Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CP1 CashFlow Statement

CashFlow Date:


Change To Liabilities:


Net Income:


Total Cash From Operating Activities:


Change To Account Receivables:


Capital Expenditures:


CP1 Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


CP1 Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Retained Earnings:




Total Current Liabilities:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


CP1 Share Price History

CP1 News

21 Jul, 2020
The Company is now in discussions with animal health partners to advance the commercialisation of DermaCann® in various regulatory and non-regulatory markets. SYDNEY, July 21, 2020 /CNW/ --Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") has released results from its safety and efficacy study for DermaCann®, an oral nutraceutical developed for healthy skin and immune function for dogs.
12 May, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
12 Feb, 2020
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
08 Jan, 2020
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") is pleased to announce that following an 18 month evaluation, it has been granted exclusive global rights to commercialise patented MicroMAX® microencapsulation technology by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) for use in the field of Animal Therapeutics.
06 Nov, 2019
CannPal Animal Therapeutics Limited's (ASX:CP1): CannPal Animal Therapeutics Limited engages in the research and...
23 Sep, 2019
The big shareholder groups in CannPal Animal Therapeutics Limited (ASX:CP1) have power over the company. Institutions...
09 Aug, 2019
CannPal Animal Therapeutics Limited (ASX:CP1) is a company with exceptional fundamental characteristics. Upon building...